Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:13:51 21/01/2026 GMT			5-day change	1st Jan Change
7.780 ^USD	+0.91%		+0.56%	-12.21%

01-15	Vanda Pharmaceuticals Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 09:00 AM
01-08	Wall Street Wavers Amid Trump's Defense Budget Plans, Driving Muted Premarket Action for US Equity Futures	MT

Press Releases

01-15	Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation	NE
01-15	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA	PR
01-08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder	PR
12-30	Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness	PR
12-11	Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference	PR
12-04	Vanda Pharmaceuticals : FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	PU
12-04	FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	PR
11-28	Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness	PR
11-17	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting	PR
11-05	Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference	PR
29/10/25	Vanda: Q3 Earnings Snapshot	AQ
29/10/25	Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results	PR
22/10/25	Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025	PR
08/10/25	Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena	PR
01/10/25	Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration	PR
25/09/25	Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"	PR
28/08/25	Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences	PR
28/08/25	Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera	PR
25/08/25	The Demise Of FDA's Administrative Summary Judgment Standard: Lessons From Vanda v. FDA	AQ
22/08/25	Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz(R)	AQ
18/08/25	In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder	PR
31/07/25	Vanda: Q2 Earnings Snapshot	AQ
31/07/25	Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results	PR
23/07/25	Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025	PR
10/06/25	Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Press Releases

Filters